Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2013 3
2014 2
2019 3
2020 1
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Doripenem versus meropenem as first-line empiric therapy of febrile neutropenia in patients with acute leukemia: a prospective, randomized study.
Oyake T, Takemasa-Fujisawa Y, Sugawara N, Mine T, Tsukushi Y, Hanamura I, Fujishima Y, Aoki Y, Kowata S, Ito S, Ishida Y. Oyake T, et al. Ann Hematol. 2019 May;98(5):1209-1216. doi: 10.1007/s00277-019-03634-w. Epub 2019 Mar 1. Ann Hematol. 2019. PMID: 30824955 Clinical Trial.
In this randomized, prospective, cooperative, open-label trial, we compared doripenem (1.0 g every 8 h) to meropenem (1.0 g every 8 h) as first-line empiric antibacterial treatment of febrile neutropenia. ...However, resolution of fever within 7 days of treatment wa …
In this randomized, prospective, cooperative, open-label trial, we compared doripenem (1.0 g every 8 h) to meropenem (1.0 g ev …
The risk of seizures among the carbapenems: a meta-analysis.
Cannon JP, Lee TA, Clark NM, Setlak P, Grim SA. Cannon JP, et al. J Antimicrob Chemother. 2014 Aug;69(8):2043-55. doi: 10.1093/jac/dku111. Epub 2014 Apr 16. J Antimicrob Chemother. 2014. PMID: 24744302
METHODS: We conducted a meta-analysis of all randomized controlled trials comparing carbapenems with each other or with non-carbapenem antibiotics to assess the risk of seizures for imipenem, meropenem, ertapenem and doripenem. RESULTS: In the risk difference (RD) a …
METHODS: We conducted a meta-analysis of all randomized controlled trials comparing carbapenems with each other or with non-carbapenem antib …
Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients.
Kays MB, Fleming MR, Cheatham SC, Chung EK, Juenke JM. Kays MB, et al. Ann Pharmacother. 2014 Feb;48(2):178-86. doi: 10.1177/1060028013512474. Epub 2013 Nov 14. Ann Pharmacother. 2014. PMID: 24259653 Clinical Trial.
OBJECTIVE: To evaluate the steady-state pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients hospitalized on a general ward. METHODS: Patients with a body mass index (BMI) 40 kg/m2 or total body weight (TBW) 100 pounds over their ideal …
OBJECTIVE: To evaluate the steady-state pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients hos …
Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I. Lucasti C, et al. Clin Ther. 2008 May;30(5):868-83. doi: 10.1016/j.clinthera.2008.04.019. Clin Ther. 2008. PMID: 18555934 Clinical Trial.
OBJECTIVE: This study was designed to compare the efficacy and safety profile of doripenem and meropenem in hospitalized adult patients with cIAI. METHODS: In this prospective, multicenter, doubleblind, noninferiority study, hospitalized adults with cIAI were random …
OBJECTIVE: This study was designed to compare the efficacy and safety profile of doripenem and meropenem in hospitalized adult …
The Status of Carbapenem Resistance in Cystic Fibrosis: A Systematic Review and Meta-Analysis.
Saadh MJ, Lohrasbi A, Ghasemian E, Hashemian M, Etemad A, Dargahi Z, Kaviar VH. Saadh MJ, et al. Yale J Biol Med. 2022 Dec 22;95(4):495-506. eCollection 2022 Dec. Yale J Biol Med. 2022. PMID: 36568834 Free PMC article. Review.
Our meta-analysis showed that trends of imipenem, meropenem, and doripenem-resistance had gradual decreases over time (1979-2021). ...The highest and lowest carbapenem resistance rates among P. aeruginosa in CF patients were shown against meropenem (23%) and …
Our meta-analysis showed that trends of imipenem, meropenem, and doripenem-resistance had gradual decreases over time (1979-20 …
Clinical efficacy of ertapenem vs. other carbapenems for the treatment of extended-spectrum-β-lactamase-producing Enterobacterales infection: A systematic review and meta-analysis.
Huang PY, Hsu CK, Liu TH, Wu JY, Tang HJ, Tsai YW, Lai CC, Chang YH. Huang PY, et al. J Glob Antimicrob Resist. 2023 Jun;33:201-207. doi: 10.1016/j.jgar.2023.03.003. Epub 2023 Mar 21. J Glob Antimicrob Resist. 2023. PMID: 36944409 Free article.
OBJECTIVE: Both ertapenem and other carbapenems, including imipenem, meropenem, and doripenem, are recommended in the treatment of extended-spectrum-beta-lactamase (ESBL)-producing Enterobacterales infection. ...
OBJECTIVE: Both ertapenem and other carbapenems, including imipenem, meropenem, and doripenem, are recommended in the treatmen …
Global mapping of antibiotic resistance rates among clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis.
Bostanghadiri N, Sholeh M, Navidifar T, Dadgar-Zankbar L, Elahi Z, van Belkum A, Darban-Sarokhalil D. Bostanghadiri N, et al. Ann Clin Microbiol Antimicrob. 2024 Mar 19;23(1):26. doi: 10.1186/s12941-024-00685-4. Ann Clin Microbiol Antimicrob. 2024. PMID: 38504262 Free PMC article. Review.
RESULT: Present analysis indicated that the highest incidences of resistance were associated with doripenem (97%), cefoxitin (96%), imipenem and cefuroxime (95%), ampicillin (94%), ceftriaxone (92%), aztreonam (91%) and meropenem (90%) which resistance to Carbapenem …
RESULT: Present analysis indicated that the highest incidences of resistance were associated with doripenem (97%), cefoxitin (96%), i …
Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems.
Zusman O, Avni T, Leibovici L, Adler A, Friberg L, Stergiopoulou T, Carmeli Y, Paul M. Zusman O, et al. Antimicrob Agents Chemother. 2013 Oct;57(10):5104-11. doi: 10.1128/AAC.01230-13. Epub 2013 Aug 5. Antimicrob Agents Chemother. 2013. PMID: 23917322 Free PMC article. Review.
In time-kill studies, combination therapy showed synergy rates of 77% (95% CI, 64 to 87%) for Acinetobacter baumannii, 44% (95% CI, 30 to 59%) for Klebsiella pneumoniae, and 50% (95% CI, 30 to 69%) for Pseudomonas aeruginosa, with low antagonism rates for all. Doripenem sh …
In time-kill studies, combination therapy showed synergy rates of 77% (95% CI, 64 to 87%) for Acinetobacter baumannii, 44% (95% CI, 30 to 59 …
Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trials.
Rice DA, Kaniga K, Lee M, Redman R. Rice DA, et al. Int J Antimicrob Agents. 2013 Apr;41(4):388-92. doi: 10.1016/j.ijantimicag.2012.12.016. Epub 2013 Feb 12. Int J Antimicrob Agents. 2013. PMID: 23410792 Clinical Trial.
An analysis of subjects with concurrent bacteraemia and either nosocomial pneumonia, complicated intra-abdominal infection or complicated urinary tract infection from six phase 3 clinical trials demonstrated similar cure rates and clearance of bacteraemia in patients treated with …
An analysis of subjects with concurrent bacteraemia and either nosocomial pneumonia, complicated intra-abdominal infection or complicated ur …
Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gram-negative pathogens: a systematic review.
Nørgaard SM, Jensen CS, Aalestrup J, Vandenbroucke-Grauls CMJE, de Boer MGJ, Pedersen AB. Nørgaard SM, et al. Antimicrob Resist Infect Control. 2019 Nov 4;8:170. doi: 10.1186/s13756-019-0624-1. eCollection 2019. Antimicrob Resist Infect Control. 2019. PMID: 31709047 Free PMC article.
The clinical and microbiological success was similar for group 1 carbapenems (imipenem, meropenem, or doripenem), group 2 carbapenems (ertapenem), and non-carbapenem antibiotics. ...
The clinical and microbiological success was similar for group 1 carbapenems (imipenem, meropenem, or doripenem), group 2 carb …
12 results